Autobahn Labs and Astellas Form Strategic Partnership to Accelerate Academic Drug Discovery

Autobahn Labs (搜索)搜索该词条, a venture studio specializing in translating academic science into investable drug discovery programs, has formed a strategic partnership with global life sciences company Astellas Pharma Inc.查看公司主页 The collaboration aims to advance academic research and discoveries into novel therapeutics while providing Astellas' Innovation Lab and Oncology Research units with integrated visibility into promising platforms, technologies and modalities from early discovery through development.

Partnership Structure and Investment Model

Under the partnership agreement, Astellas will receive exclusive opportunities to invest in selected drug discovery programs emerging from Autobahn's translational research pipeline, which encompasses promising, early-stage discoveries from leading academic institutions. In return, Autobahn will receive an annual access fee and co-investment from Astellas in startups created under the partnership framework.

The collaboration establishes a unique equity-sharing model where selected early-stage research and discovery programs will be advanced within newly formed Program Companies. Equity interests in these ventures will be distributed among four key stakeholders: Autobahn, Astellas, the originating academic institution, and the founding academic investigators.

Licensing and Commercialization Rights

Astellas has secured a right of first negotiation for exclusive licenses to further develop and commercialize intellectual property arising from jointly funded programs. This arrangement provides the pharmaceutical giant with preferential access to promising therapeutic candidates while maintaining the collaborative nature of the partnership.

Leadership Perspectives

"This exciting partnership combines the strengths of academic innovation with world-class drug development expertise," said Dushyant Pathak, CEO of Autobahn. "By combining Autobahn's deep academic relationships and search and evaluation capabilities with Astellas' drug development expertise, our goal is to accelerate the translation of breakthrough discoveries into meaningful therapies for patients."

Morten Sogaard, PhD, Head of Astellas Innovation Lab, emphasized the strategic importance of the collaboration: "Astellas' external innovation strategy is anchored in building strong partnerships with innovative academic leaders and ambitious start-ups to advance promising science with the potential to address high unmet patient needs. Partnering with Autobahn Labs (搜索)搜索该词条 gives us a unique window into early-stage, high potential programs grounded in strong science, and an opportunity to access cutting-edge research programs from top-tier academic research centers."

Autobahn's Academic Network

Autobahn Labs (搜索)搜索该词条 operates as a venture studio that partners with leading academic institutions to translate cutting-edge science into de-risked drug discovery programs. The company is backed by Samsara BioCapital (搜索)搜索该词条 and Charles River Labs (搜索)搜索该词条 and has established institutional collaborations with prestigious research centers including the University of California Los Angeles (搜索)搜索该词条 (UCLA), University of California San Francisco查看公司主页 (UCSF), University of California San Diego查看公司主页 (UCSD), the University of Southern California查看公司主页 (USC), Cold Spring Harbor Laboratory (搜索)搜索该词条, the University of Pennsylvania查看公司主页, Boston Children's Hospital查看公司主页, the Salk Institute for Biological Studies (搜索)搜索该词条, and the University of Michigan查看公司主页.

The partnership represents a strategic approach to bridging the gap between academic research and pharmaceutical development, potentially accelerating the timeline for bringing innovative therapies from laboratory bench to patient bedside.